StreetInsider.com News Articles

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.
Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.
Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.

Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.

Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN)

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions

Wed, 13 May 2026 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the results of resolutions presented at its Combined General Meeting (CGM), held on May 11, 2026, and made them available on the dedicated section of its website
All resolutions recommended by the Board and submitted to the Combined General Meeting were adopted. 77.83% of the capital was present and represented.
The results of the votes on all proposed resolutions can be found on Sensorion's website (